Guardant Health is a pioneer in non-invasive cancer diagnostics and the first company to commercialize a comprehensive genomic liquid biopsy.

Transforming cancer care

Our proprietary digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. We have combined decades of scientific research, advances in laboratory technology, and our breakthrough innovation in liquid biopsy to create a test that has already handled tens of thousands of samples.

Tumors evolve, treatment must too

Our current products are just the beginning of what we hope to accomplish, and new uses of our platform are emerging.

Today liquid biopsies are largely a tool for therapy selection for advanced cancers. We believe that some day their utility will cover the entire cancer-care continuum. Liquid biopsies may soon be a tool for early detection, an aid in neoadjuvant and adjuvant therapy, and a non-invasive method for residual disease monitoring and recurrence monitoring.

We know cancer is a dynamic disease and evolves in the face of treatment, and understanding that evolution is critical to developing new treatment plans. We have built a massive database of genomic information about how advanced cancers respond to therapy, which will help us map the paths cancers take when under treatment pressure.

The more detail we add to this map, the better we will understand the disease, and the sooner we can hope to defeat it. We believe this resource can accelerate new drug development and improve the lives of all patients fighting cancer.

Our Team

To achieve our goal of turning cancer into manageable disease, we’ve drawn leadership from diverse disciplines and sectors including genomic sequencing, clinical oncology, digital signal processing, bioinformatics, healthcare reimbursement, laboratory operations, consumer web and mobile applications, and biopharmaceuticals.

Helmy Eltoukhy, PhD

Chief Executive Officer

Helmy is an entrepreneur and pioneer in the biotech industry. After receiving his PhD, MS and BS degrees in electrical engineering from Stanford University, he joined the Stanford Genome Technology Center (SGTC) as a post-doctoral fellow in 2006 to work on low-cost DNA sequencing technologies. During his doctoral studies and at the SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several NHGRI grants. In 2007, he co-founded Avantome to commercialize semiconductor sequencing to help speed up the democratization of high throughput DNA sequencing. At Illumina, Helmy was Senior Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems.

AmirAli Talasaz, PhD

President & COO

AmirAli is an entrepreneur in the rare genomics and clinical diagnostics fields. Prior to co-founding Guardant, he was Senior Director of Diagnostics Research at Illumina and led the efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different genomic technologies suitable for clinical applications. Before Illumina, he founded Auriphex Biosciences, which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by Illumina in 2009. During his academic years, he led the Technology Development group at Stanford Genome Technology Center. AmirAli received his PhD in electrical engineering and MSc in management science from Stanford University.

Michael Wiley, JD, CPA

Chief Legal Officer

Michael joined Guardant Health in 2012 as Chief Financial Officer and became its Chief Legal Officer in 2016. Prior to joining Guardant, Michael worked as CFO at Voyage Medical, a medical device company. Before Voyage, Michael was VP of Finance at Microchip Biotechnologies, Inc., where he led the team that raised both Series A and Series B financings for the company. Earlier in his career, Michael was a corporate attorney at Venture Law Group and acted as in-house associate counsel for Novell where he focused on intellectual property and employment issues. Before receiving a JD J. Reuben Clark Law School at Brigham Young University, Michael worked for KPMG as a tax accountant.

Rick Lanman, MD

Chief Medical Officer

As Chief Medical Officer, Dr. Richard Lanman is responsible for clinical studies, publications, and physician education at Guardant Health. Richard previously served as the Chief Medical Officer of Veracyte, where he managed collaborations with academic and community-based physician thought leaders. He also led the studies and publications resulting in broad managed care coverage for the Afirma thyroid cancer test. Previously, he served as Chief Medical Officer for two cardiovascular biodiagnostic companies, diaDexus and Atherotech. Prior to Atherotech, Richard was the medical director and senior vice president of San Jose Medical Group and a chief of quality at Kaiser Permanente. He completed his internship and residency at the University of California San Francisco, after receiving an MD from Northwestern University and a BS in chemistry from Stanford University, where he graduated Phi Beta Kappa.

Leena Das-Young, Pharm. D.

General Manager and Chief LUNAR Officer

Dr. Das-Young oversees all work applying Guardant Health’s technology and database of more than 70,000 clinical Guardant360® assay results, toward new applications in early-stage cancer, such as residual detection, recurrence monitoring, and early detection of cancer. Dr. Das-Young was most recently the Vice President & Head of the Late Phase Strategy and Development Group in Pfizer in the Oncology group and was responsible for a portfolio of oncology programs including Ibrance, Xalkori, Besponsa, Sutent, lorlatinib, and others. Prior to her roles in product development, she served in increasingly senior commercial roles responsible for several successful launches in both Pfizer and Bayer. She received her B.S. and Doctor of Pharmacy degrees from Purdue University.

Mark Jacobstein

Chief User Engagement Officer

Mark has held numerous senior executive roles in mobile software and consumer Internet companies since 1994, when he founded the world’s first online fantasy sports company, Small World Sports, as well as the first web agency in New York City. Mark was co-founder and President of Digital Chocolate, and an EVP at loopt. Most recently, Mark was CEO of mobile VoIP pioneer iSkoot before its acquisition by Qualcomm, where Mark served as Vice President of Qualcomm iSkoot Technologies. He holds a BA in Computer Science from Harvard University.

Derek Bertocci

Chief Financial Officer

Derek is responsible for all finance and accounting functions within Guardant Health. He has more than two decades of experience leading the finance operations of life science and biotechnology companies. He served as CFO of VISX, the developer of laser vision correction, as well as Laserscope, BioForm Medical, Accuray Incorporated, and most recently Achaogen, where he oversaw its successful initial public offering.

Bill Smith, JD, MPA

Senior Vice President, Intellectual Property

Bill has decades of experience handling complex biotechnology patent matters, with a focus on building world-class patent estates protecting groundbreaking platform inventions. He most recently served as the General Counsel and Executive Vice President of Legal Affairs for Fluidigm Corporation. Prior to Fluidigm, Bill founded the biotechnology practice at Townsend & Townsend (now Kilpatrick Townsend & Stockton), one of the country’s top intellectual property law firms. He holds a JD/MPA from the University of Southern California’s Law Center and a BA in Biology from UC San Diego.

Andy Ament

Vice President, Operations

Andy is responsible for Operations at Guardant Health, overseeing Clinical Operations, Research Operations, Engineering, Quality, Supply Chain, and Facilities. Andy brings experience scaling operations in biotech companies such as Incyte Genomics, Genitope Corporation, and Genomic Health. In his most recent role as VP of Operations at Adaptive Biotechnologies, Andy led two CAP/CLIA Reference Laboratories, as well as Process Engineering, Facilities, and Supply Chain teams in South San Francisco and Seattle.

Darya Chudova, PhD

Vice President, Bioinformatics

Darya leads Guardant Health’s growing bioinformatics function and has deep experience developing analytical methods and software for interpreting genomic sequencing data for Illumina and Veracyte. She has an extensive background in probability and machine learning, and her work exploring the use of genomic sequencing in non-invasive prenatal testing has been published in the New England Journal of Medicine. She holds a PhD in computer science from the University of California, Irvine.

Morteza Minaee, LP.D

Vice President, Regulatory Affairs

Mort has more than 25 years of experience in the FDA-regulated medical devices and global diagnostic industry leading regulatory, quality-systems, and clinical-affairs organizations. Prior to Guardant Health, he served as Senior Director, Regulatory Affairs at Roche resulting in FDA clearances of multiple digital pathology applications including breast cancer biomarkers. Previously he also held senior positions in Regulatory, Clinical Affairs, and Quality for companies such as Abbott Molecular and Siemens Healthcare. He holds a doctorate in law and policy from Northeastern University, and MS in administration from Boston University.

Daniel Simon

Senior Vice President, BioPharma Business Development

Daniel is responsible for building our partnerships with pharmaceutical and biotechnology companies. He brings more than a decade of experience in the life sciences industry across business development, strategy, and operations. Previously, Daniel served in roles at MyoKardia, Onyx Pharmaceuticals, McKinsey & Company, and Genentech. He holds an MBA from the University of Pennsylvania's Wharton School and an MA Hons. in Natural Sciences from the University of Cambridge.

Stan Skrzypczak

Vice President, Corporate Development and Reimbursement

Stan has more than 25 years of global experience in both diagnostics and cancer therapeutics. He has held senior strategic commercial, reimbursement, and business development roles at Genentech, Genomic Health, and Invitae. He currently leads US reimbursement efforts and international commercial development. He holds an MBA in Marketing and a MS in Immunology and Microbiology. 

Guardant Health AMEA, Inc.

Simranjit Singh

CEO, Guardant Health
AMEA, Inc.

Simranjit Singh is the CEO of Guardant Health AMEA, Inc., a joint venture between Guardant Health, Inc. & Softbank. He has 15 years of senior management experience in Asia Pacific working with biopharma, diagnostics, and medical device companies for their R&D, business expansion, and growth strategies for the region. He was the Vice President of the medical devices, and diagnostics business for IQVIA. He was instrumental in leading the IQVIA’s growth strategy for Asia pacific and accelerating revenue growth. Simranjit also served as the Chairman for BioSingapore & plays an integral role to develop the biomedical sector in Singapore. He was also the Vice-Chairman of the Korea Health Industry Development Institute (KHIDI) Global Biopharma KOL program.
Simranjit holds a Bachelors Degree in Biomedical Sciences from the National University of Singapore and Grad. Dip in Bio-entrepreneurship from the University of Pennsylvania (UPENN). He also has a Masters in Business Administration from the Graduate School of Business, University of Chicago.

Our Advisors

Maurice Stroun, PhD

Professor, University of Geneva

David S Hoon, PhD

Head of Molecular Oncology Research, John Wayne Cancer Institute

Eric Topol, MD

Director, Scripps Translational Science Institute

Razelle Kurzrock, MD

Senior Deputy Director for Clinical Science, UC San Diego Moores Cancer Center

David Gandara, MD

Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center

Ronald W. Davis, PhD

Professor of Biochemistry and Genetics, Stanford School of Medicine

Our Investors

Sequoia Capital
Khosla Ventures
Lightspeed Venture Partners
Soft Bank

Our Partners

We work with bio-pharmaceutical partners, digital health companies, patient advocacy groups and international distributors to make sure our products provide the greatest benefit. If you are interested in building partnerships to improve care for cancer patients, we want to know.

Our Board

Helmy Eltoukhy, PhD

Chief Executive Officer

AmirAli Talasaz, PhD

President & COO

Samir Kaul

General Partner, Khosla Ventures

Aaref Hilaly

Partner, Sequoia Capital

Ian Clark

Ex-CEO, Genentech